AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?

Impact · against what's priced in

AtriCure shows positive momentum based on accelerated clinical trial enrollment and reiterated long-term revenue targets. While the stock has already rallied 6.2%, the acceleration of the BoxX-NoAF trial represents a material catalyst for expanding the company's addressable market.

ATRC+0.50

No priced-in read yet

In context

Accelerated enrollment in the BoxX-NoAF trial and the reiteration of a $1 billion revenue goal by 2030 provide concrete growth catalysts and potential market expansion.

Read from the article alone

• revenue growth▲9%
• healthcare▲2%
• earnings
• ATRC
• QDEL
• clinical trials
• growth prospects
• medical devices